Transforming growth factor-beta-1 latency-associated peptide and soluble betaglycan prevent a glucose-induced increase in fibronectin production in cultured human mesangial cells. 2002

Kayoko Nomura, and Hisaya Tada, and Koji Kuboki, and Toshiki Inokuchi
Research Division, Second Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan. kayoko-n@nifty.com

This study was performed to investigate the effects of transforming growth factor-beta1 (TGF-beta1) latency-associated peptide (LAP) and betaglycan on TGF-beta1 activity, and on the glucose-induced overproduction of fibronectin in cultured human mesangial cells (MCs). We found that recombinant LAP and recombinant soluble betaglycan decrease the active form of TGF-beta1, measured by ELISA, in a dose-dependent manner in a cell-free system. The effective dosages of LAP and soluble betaglycan for a 50% reduction were approximately 20- and 75-fold of the TGF-beta1 concentration, respectively. The active form of TGF-beta1 in the media secreted from MCs was significantly (p < 0.01) reduced by the addition of 10 nmol/l LAP and 10 nmol/l soluble betaglycan with no significant change in total (active + latent) TGF-beta1. Recombinant LAP and soluble betaglycan also inhibited a recombinant TGF-beta1-stimulated increase in fibronectin production in MCs. Furthermore, the glucose-induced increase in fibronectin secreted from MCs was significantly (p < 0.01) suppressed by concomitant incubation with LAP or soluble betaglycan, while these agents had no effect on fibronectin production under physiological glucose concentrations. These results indicate that recombinant LAP and soluble betaglycan suppress the glucose-induced overproduction of fibronectin presumably via inhibition of TGF-beta1 activity in MCs. Further in vivo studies are needed to define the possible beneficial effects of these agents in diabetic nephropathy.

UI MeSH Term Description Entries
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011498 Protein Precursors Precursors, Protein
D011509 Proteoglycans Glycoproteins which have a very high polysaccharide content. Proteoglycan,Proteoglycan Type H
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D005353 Fibronectins Glycoproteins found on the surfaces of cells, particularly in fibrillar structures. The proteins are lost or reduced when these cells undergo viral or chemical transformation. They are highly susceptible to proteolysis and are substrates for activated blood coagulation factor VIII. The forms present in plasma are called cold-insoluble globulins. Cold-Insoluble Globulins,LETS Proteins,Fibronectin,Opsonic Glycoprotein,Opsonic alpha(2)SB Glycoprotein,alpha 2-Surface Binding Glycoprotein,Cold Insoluble Globulins,Globulins, Cold-Insoluble,Glycoprotein, Opsonic,Proteins, LETS,alpha 2 Surface Binding Glycoprotein
D005920 Glomerular Mesangium The thin membranous structure supporting the adjoining glomerular capillaries. It is composed of GLOMERULAR MESANGIAL CELLS and their EXTRACELLULAR MATRIX. Mesangium, Glomerular,Mesangial Extracellular Matrix,Extracellular Matrices, Mesangial,Extracellular Matrix, Mesangial,Glomerular Mesangiums,Matrices, Mesangial Extracellular,Matrix, Mesangial Extracellular,Mesangial Extracellular Matrices,Mesangiums, Glomerular
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D053773 Transforming Growth Factor beta1 A subtype of transforming growth factor beta that is synthesized by a wide variety of cells. It is synthesized as a precursor molecule that is cleaved to form mature TGF-beta 1 and TGF-beta1 latency-associated peptide. The association of the cleavage products results in the formation a latent protein which must be activated to bind its receptor. Defects in the gene that encodes TGF-beta1 are the cause of CAMURATI-ENGELMANN SYNDROME. TGF-beta1,Transforming Growth Factor-beta1,TGF-beta-1,TGF-beta1 Latency-Associated Protein,TGF-beta1LAP,Transforming Growth Factor beta 1 Latency Associated Peptide,Transforming Growth Factor beta I,Latency-Associated Protein, TGF-beta1,TGF beta 1,TGF beta1 Latency Associated Protein,TGF beta1LAP
D018125 Receptors, Transforming Growth Factor beta Cell-surface proteins that bind transforming growth factor beta and trigger changes influencing the behavior of cells. Two types of transforming growth factor receptors have been recognized. They differ in affinity for different members of the transforming growth factor beta family and in cellular mechanisms of action. Receptors, TGF-beta,TGF-beta Receptors,Transforming Growth Factor beta Receptors,TGF-beta Receptor,Transforming Growth Factor beta Receptor,Receptor, TGF-beta,Receptors, TGF beta,TGF beta Receptor,TGF beta Receptors

Related Publications

Kayoko Nomura, and Hisaya Tada, and Koji Kuboki, and Toshiki Inokuchi
December 2006, Nephrology (Carlton, Vic.),
Kayoko Nomura, and Hisaya Tada, and Koji Kuboki, and Toshiki Inokuchi
March 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
Kayoko Nomura, and Hisaya Tada, and Koji Kuboki, and Toshiki Inokuchi
November 1995, Chinese medical journal,
Kayoko Nomura, and Hisaya Tada, and Koji Kuboki, and Toshiki Inokuchi
August 2001, Kidney international,
Kayoko Nomura, and Hisaya Tada, and Koji Kuboki, and Toshiki Inokuchi
December 1998, Kidney international,
Kayoko Nomura, and Hisaya Tada, and Koji Kuboki, and Toshiki Inokuchi
July 1994, Investigative ophthalmology & visual science,
Kayoko Nomura, and Hisaya Tada, and Koji Kuboki, and Toshiki Inokuchi
April 1993, Nihon Jinzo Gakkai shi,
Kayoko Nomura, and Hisaya Tada, and Koji Kuboki, and Toshiki Inokuchi
December 1992, Kidney international,
Kayoko Nomura, and Hisaya Tada, and Koji Kuboki, and Toshiki Inokuchi
February 1994, Cancer research,
Copied contents to your clipboard!